The Role of Prostaglandin Analogues in the Treatment of Glaucoma in the 21st Century

International Ophthalmology Clinics

Volumn 44, Issue 2, 2004, Pages 15-27

  Nguyen, Quang H ^a  

^a SCRIPPS CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIMATOPROST; LATANOPROST; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN F2 ALPHA DERIVATIVE; TRAVOPROST; UNOPROSTONE ISOPROPYL ESTER;

CONJUNCTIVAL HYPEREMIA; DOSE CALCULATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MARKETING; DRUG MECHANISM; DRUG MEGADOSE; DRUG NOMENCLATURE; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; ESTERIFICATION; EYE IRRITATION; FIRST PASS EFFECT; FOOD AND DRUG ADMINISTRATION; GLAUCOMA; HUMAN; HYPEREMIA; HYPERTRICHOSIS; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; RETINA MACULA CYSTOID EDEMA; REVIEW; STRUCTURE ACTIVITY RELATION;

ANTIHYPERTENSIVE AGENTS; GLAUCOMA; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INTRAOCULAR PRESSURE; PROSTAGLANDINS;

EID: 1942469965     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004397-200404420-00004     Document Type: Review

References (26)

1. Bhattacherjee P. Prostaglandins and inflammatory reactions in the eye. Methods Find Expt Clin Pharmacol. 1980;2:17-31.
2. Bito LZ. A new approach to the medical management of glaucoma, from the bench to the clinic, and beyond. The Proctor Lecture. Invest Ophthamol Vis Sci. 2001;42:1126-1133.
3. Bito LZ, Draga A, Blanco J, et al. Long-term maintenance of reduced intraocular pressure by daily or twice daily topical application of prostaglandins to cat or rhesus monkey eyes. Invest Ophthalmol Vis Sci. 1983;24:312-319.
4. Giuffre G. The effects of prostaglandin F2α in the human eye. Grafes Arch Clin Exp Opthalmol. 1985;222:139-141.
5. Voet D, Voet JG. Lipid metabolism: prostaglandins, prostacyclins, thromboxanes, and leukotrienes. In: Biochemistry. New York, NY: John Wiley & Sons; 1990:658-665.
6. Campell WB, Halushka PV. Lipid-derived autocoids. Eicosanoids and platelet-activating factor. In: Hardman JG, Limbird LE, et al, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw Hill; 1990:601-605.
7. Stjernschantz JW. From PGF2α isopropyl ester to latanoprost: a review of the development of Xalatan. The Proctor Lecture. Invest Ophthalmol Vis Sci. 2001;42:1134-1145.
8. Resul B, Stjernschantz J. Structure-activity relationships of prostaglandin analogues as ocular hypotensive agents. Curr Opin Therapeut Patterns. 1993;3:781-795.
9. Resul B, Stjernschantz J, Selen G, et al. Structure activity relationships and receptor profiles of some ocular hypotensive prostanoids. Surv Ophthalmol. 1997;41(suppl 2):S47-S52.
10. Villumsen J, Ahn A. Prostaglandin F2α isopropylester eye drops: effects in normal human eyes. Br J Ophthalmol. 1989;73:419-426.
11. Basu S, Sjoquist B, Stjernschantz J, et al. Corneal permeability to and ocular metabolism of phenyl substituted prostaglandin esters in vitro. Prostaglandins Leukot Essent Fatty Acids. 1994;50:161-168.
12. Stjernschantz J, Resul B. Phenyl substituted prostaglandin analogs for glaucoma treatment. Drugs Future. 1992;17:691-704.
13. Waterbury LD, Eglen RM, Faurot GF, et al. EP3 but not EP2, FP or TP prostanoid receptor stimulation may reduce intraocular pressure. Invest Ophthalmol Vis Sci. 1990;31:2560-2567.
14. Camras CB, Siebold EC, Lustgarten JS, et al. Maintained reduction of intraocular pressure by prostaglandin F2-alpha-isopropyl ester applied in multiple doses in ocular hypertension, and glaucoma patients. Ophthalmol. 1989;96:1329-1337.
15. Lindsey JD, Kashiwagi K, Kashiwagi F, et al. Prostaglandins alter extracellular matrix adjacent to human ciliary muscles. Invest Ophthalmol Vis Sci. 1997;38:2214-2223.
16. Weinreb RN, Kashiwagi K, Kashiwagi F, et al. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci. 1997;38:2772-2780.
17. Ziai N, Dolan JW, Kacere RD, et al. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 Alpha analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol. 1993;111:1351-1358.
18. Maxey KM, Johnson JC, LaBrecque J. The hydrolysis of bimatoprost in corneal tissue generates a potent prostamide FP receptor agonist. Surv Ophthalmol. 2002;47(suppl 1):S34-S40.
19. Camras CB, Sjoquist B, Toris CB, et al. The hydrolysis of bimatoprost to its free acid in human eyes in vivo. Presented at: Annual Meeting of the American Academy of Ophthalmology; 2003; Anaheim, California; scientific poster 198.
20. Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132:472-484.
21. Stewart WC, Kolker AE, Stewart JA, et al. Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost. Am J Ophthalmol. 2003;135:314-320.
22. Feldman RM. Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension. J Ocular Therapeut. 2003;19:23-35.
23. DuBiner H, Cooke D, Dirkds M, et al. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol. 2001;45(suppl 4):S353-S360.
24. Gandolfi S, Simmons ST, Sturm R, et al. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther. 2001;18:110-121.
25. Noecker RS, Dirks MS, Choplin NT, et al. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Opthalmol. 2003;135:55-63.
26. Parrish RK, Palmberg P, Wang-Pui S. for the XLT study group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: A 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135:688-703.